Chubb Ltd maintained its position in Merck & Company, Inc. (NYSE:MRK) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 300,000 shares of the company’s stock at the end of the first quarter. Merck & makes up approximately 8.2% of Chubb Ltd’s holdings, making the stock its 4th largest position. Chubb Ltd’s holdings in Merck & were worth $19,062,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Intellectus Partners LLC bought a new stake in shares of Merck & during the fourth quarter worth $103,000. Vigilant Capital Management LLC boosted its stake in shares of Merck & by 16.7% in the first quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock worth $111,000 after buying an additional 250 shares during the last quarter. Gradient Investments LLC boosted its stake in shares of Merck & by 41.3% in the first quarter. Gradient Investments LLC now owns 2,306 shares of the company’s stock worth $147,000 after buying an additional 674 shares during the last quarter. Pinnacle Bank bought a new stake in shares of Merck & during the first quarter worth $152,000. Finally, Tortoise Investment Management LLC boosted its stake in shares of Merck & by 50.6% in the fourth quarter. Tortoise Investment Management LLC now owns 2,678 shares of the company’s stock worth $158,000 after buying an additional 900 shares during the last quarter. 73.46% of the stock is currently owned by institutional investors.
Merck & Company, Inc. (NYSE:MRK) traded down 0.57% during trading on Friday, reaching $61.49. The company’s stock had a trading volume of 8,421,689 shares. The company has a market cap of $167.71 billion, a P/E ratio of 33.29 and a beta of 0.80. Merck & Company, Inc. has a 52 week low of $58.29 and a 52 week high of $66.80. The company’s 50 day moving average price is $62.91 and its 200 day moving average price is $63.83.
Merck & (NYSE:MRK) last posted its quarterly earnings data on Friday, July 28th. The company reported $1.01 EPS for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.14. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The company had revenue of $9.93 billion during the quarter, compared to the consensus estimate of $9.75 billion. During the same period in the prior year, the business posted $0.93 EPS. The company’s quarterly revenue was up .9% on a year-over-year basis. On average, equities analysts anticipate that Merck & Company, Inc. will post $3.87 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 6th. Stockholders of record on Friday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date is Thursday, September 14th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 3.06%. Merck &’s dividend payout ratio is 76.11%.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by BNB Daily and is the sole property of of BNB Daily. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.baseball-news-blog.com/2017/08/19/merck-company-inc-nysemrk-stake-held-by-chubb-ltd-updated-updated.html.
A number of brokerages have recently weighed in on MRK. HSBC Holdings plc upgraded Merck & from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 9th. BidaskClub cut Merck & from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. Zacks Investment Research cut Merck & from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. UBS AG raised their target price on Merck & from $70.00 to $72.00 and gave the company a “buy” rating in a research report on Monday, July 31st. Finally, Piper Jaffray Companies set a $70.00 price target on Merck & and gave the company a “buy” rating in a research note on Saturday, July 29th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $69.58.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.